Every pharma brand begins with one message. A cross-functional team spends months defining it: the indication statement, the efficacy claim with its qualifier, the safety language that must travel with it, the positioning against the standard of care. Medical signs it, regulatory signs it, legal signs it. By launch it exists as a claims grid, a message house, a strategy on a page. For one moment, usually the moment the grid is approved, the company has exactly what it set out to build: a single message it can defend to a regulator and repeat to a prescriber.
Then execution begins, and the company starts losing the thing it just approved.
Not through negligence, and not at any single point. The message erodes through the ordinary mechanics of scale. It is adapted for a congress booth, compressed into a banner, localized for an affiliate, paraphrased in a triggered email, summarized in a slide, and finally restated by an AI assistant to a clinician who never opens any of those assets. Every step is individually reasonable. The sum is a gap between the strategy the company approved and the message the market actually receives. That gap has a name: the strategy execution gap. Pharma does not have a message definition problem; it defines and approves messages with more rigor than almost any industry. It has a message execution problem, and it concentrates at four points in the content lifecycle.
The scale that breaks the message
Message control was a manageable problem when a brand shipped a detail aid, a leave-behind, and a website. It stopped being manageable when content industrialized. Veeva's Pulse Content Metrics benchmark, built on anonymized data from more than 350 global pharma companies, found the volume of commercial content under management compounding at roughly 70 percent per year. Veeva's more recent Pulse Field Trends research adds the second half of the picture: nearly 80 percent of approved content is rarely or never used.
Read together, those two findings describe the condition the strategy execution gap grows in. Companies produce message-bearing assets at a compounding rate, most of those assets never earn sustained use, and no number anyone reports says whether the message inside them survived the trip. Volume is scaling. Fidelity is not even being watched. Nobody decided that trade. It accumulated, one asset at a time.
Four friction points where the approved message erodes
The erosion is not random. It concentrates at four stages of the lifecycle, and each stage fails in its own characteristic way.
Create. No team executes a claims grid verbatim. Writers and agencies adapt it: shortened for a banner, warmed for a patient page, sharpened for a congress panel, translated for a market. Each adaptation is a small act of re-authorship, and it is usually done from whatever artifact was closest to hand, last quarter's deck, an earlier asset, memory, rather than from the approved source. Multiply that across channels, markets, and agency partners at the rate the industry is producing content, and the approved message becomes a family of near-relatives: each slightly different, none formally wrong, all drifting.
Review. MLR is where drift should be caught, and it is: repeatedly, expensively, and late. Reviewers find the same categories of issue asset after asset, a claim stated without its qualifier, safety language dropped in compression, a reference that no longer supports the sentence it is attached to, failures that are mechanical and detectable long before a human reviewer opens the file. Industry analyses put typical MLR cycles at 50 to 60 days per content piece. The reviewer is the control, and the control works. But review sits at the end of creation, so every recurring mechanical error costs a full cycle to detect, and the correction arrives after the drift has been authored, sometimes after a sibling asset has shipped. The lesson of the MLR backlog is not that reviewers are slow. It is that the process upstream keeps mass-producing a class of error the process downstream can only catch one asset at a time.
Measure. Content operations dashboards answer the questions they were built to answer: how many assets shipped, how fast they cleared review, how often modules were reused, how the channel engaged. None of those numbers observes the message. A brand can hit every operational KPI, velocity up, reuse up, engagement steady, while the approved message fragments underneath, because nothing compares what went out against what was approved. Teams measure the container, not the contents, and what is not measured is not managed.
Interpret. The newest friction point sits outside the company entirely. When a clinician asks ChatGPT, Gemini, Perplexity, or Claude about a therapy, or reads a Google AI Overview above the search results, the answer is assembled from whatever those systems retrieved: perhaps your approved content, perhaps a competitor's framing, perhaps an outdated guideline or a forum thread. The answer can omit the qualifier, alter the population, or extend the claim beyond what the label supports, and it reaches the reader with the same fluent confidence either way. This audience is not marginal. The American Medical Association's March 2026 physician survey found that 81 percent of physicians already use AI professionally, and Doximity's 2026 State of AI in Medicine report found literature search the most common use among physicians applying AI in clinical practice. The last mile of message execution now runs through machines the brand does not operate and cannot brief.
The cause: four stages, four sources of truth
It is tempting to treat each friction point as its own problem with its own tool: better templates for Create, more reviewers for Review, a new dashboard for Measure, a monitoring vendor for Interpret. That treats symptoms. The underlying cause is structural, and it is the same at all four points: no shared message model connects them.
Look at where each stage keeps its truth. What was approved lives in a claims grid and the label. What was created lives in a DAM as finished, flattened assets. What passed review lives in the MLR system as verdicts and annotations. What AI communicates lives nowhere inside the company at all. Four stages, four disconnected artifacts, and no representation of the message that survives from one to the next.
The consequences follow mechanically. Creation cannot check itself against approval, because the approved message is a document, not a model. Review cannot teach creation, because its findings are trapped in per-asset annotations that never flow upstream. Measurement cannot score fidelity, because there is nothing machine-comparable to score against. Monitoring cannot classify an AI answer as on-message or off, because the message was never expressed in a form a machine can compare. The strategy execution gap, seen structurally, is exactly this: the message exists as prose at the top of the lifecycle and as scattered fragments everywhere else.
The fix: one approved source of truth, and a loop around it
The fix follows directly from the cause. If the gap exists because four stages answer to four artifacts, close it by anchoring all four to one: the approved message, held as a structured, versioned model, every claim tied to its evidence, every qualifier bound to the claim it protects, every boundary explicit, that each stage reads from and reports back to. Governing message execution then becomes an operating loop with three motions.
Define. The approved message is captured once, as structure rather than prose. This is not new approval work; it is the claims grid and label the company already has, made machine-readable and versioned, so the question "what did we approve" has exactly one current answer, and a label change propagates from one place.
Execute. Creation and review both anchor to that model. Writers adapt from the source rather than from the nearest old asset, and drafts are checked against the model before submission, so the recurring mechanical failures, the dropped qualifier, the missing safety statement, the stale reference, surface in minutes instead of consuming a multi-week review cycle. The reviewer still decides. The point is to back the MLR reviewer with a cleaner queue and a Part 11-supporting trail of what was checked against which message version, never to replace their judgment.
Learn. Measurement and monitoring read against the same model. Inside, fidelity becomes a first-class metric: how much of what shipped preserved the approved message intact. Outside, AI answers are compared to the same source of truth, so an omission, an alteration, or an extension beyond the approved message is a classified finding tied to a specific claim and version, not a screenshot in a slide. And what Learn finds feeds Define and Execute: a claim the engines consistently garble is a claim to restate or support better. The loop closes.
None of this asks the company to approve anything new. It asks the company to stop letting the thing it already approved dissolve into copies.
A worked example: Varigel
Take Varigel, a fictional brand approved for one narrow indication, with an efficacy claim that carries a qualifier and a contraindication for patients on a common comorbidity medication.
The gap version of Varigel's year looks like this. Create: eleven assets across four channels each restate the efficacy claim a little differently, and two drop the qualifier in compression. Review: MLR catches one of the two, six weeks after it was authored, and the correction never reaches the sibling asset already in market. Measure: the content dashboard reports reuse up and cycle time improving, so the quarter reads as a success. Interpret: asked what Varigel is for, one engine states the indication cleanly, two extend it to the broader population the label excludes, and none volunteer the contraindication. Every function did its job. The message still leaked at all four points, and nobody can see the leak, because nothing compares the four stages to each other.
Now run the same brand through the loop. Define: Varigel's indication, efficacy claim with its qualifier, and contraindication exist once, as a versioned message model. Execute: the banner adaptation is drafted from the model and pre-checked against it, the dropped qualifier is flagged before submission, and MLR reviews a clean asset instead of spending a cycle on a mechanical error. Measure: the quarterly report now includes fidelity, which shows the congress deck and one email diverging from the approved efficacy framing, a fixable finding instead of an invisible one. Interpret: the same model scores AI answers, so the two engines extending the indication register as documented findings against a specific claim, and closing that exposure becomes the priority for what the brand publishes next. Same team, same volume, same reviewers. The difference is that all four stages now answer to the message that was actually approved.
Where this leaves you
The strategy execution gap is not a failure of effort. Pharma companies spend heavily at every one of the four stages; the spend simply is not connected. What is missing is the layer underneath: one approved message, held in a form every stage can be governed against, with a loop that runs Define, Execute, Learn instead of four functions each keeping their own truth.
That layer is what Juncture is built to be: the approved message intelligence layer for pharma. The platform anchors content creation, pre-MLR checking, and AI answer monitoring to a single approved source of truth, and how it works walks the Define, Execute, Learn loop end to end. If the Interpret stage is the one that worries you most, Answer Monitor measures what ChatGPT, Gemini, Perplexity, Google AI Overviews, and Claude actually say about your brand against the same approved message everything else is held to. You approved one message. The work now is making sure that is the one the market hears.
Sources
- pharmaphorum with Veeva, "Utilising content metrics to improve digital engagement" (Veeva Pulse Content Metrics: data across 350+ global pharma companies, roughly 70 percent compound annual growth in managed content volume). pharmaphorum.com
- Veeva, "Veeva Pulse Report Finds Content-Driven Engagement Lags Despite Proven Boost to Treatment Adoption" (nearly 80 percent of approved content rarely or never used). veeva.com
- Indegene, "Is the MLR Review Process Slowing Pharma Marketing?" (MLR cycles of 50 to 60 days per content piece). indegene.com
- American Medical Association, "More than 80% of physicians use AI professionally, AMA survey," March 2026. ama-assn.org
- Doximity, "2026 State of AI in Medicine Report." doximity.com